GENEIII

GENEIII is a synthetic biotechnology company founded in 2021 and headquartered in Nanjing, China. The company specializes in the large-scale production of high-purity (99.99%) L-Ergothioneine (EGT) using a patented, sustainable fermentation process. GENEIII operates an end-to-end synthetic biology platform that encompasses strain engineering, precision fermentation, and purification, significantly reducing production costs compared to traditional methods. The company distinguishes itself by pursuing a pharmaceutical-level approach to efficacy validation, conducting over 30 human clinical trials across various indications, including liver health, eye health, and cognitive function. GENEIII's L-Ergothioneine has achieved U.S. FDA GRAS status at a record 150 mg dose, positioning the company as a leading B2B supplier and consumer health innovator in the global longevity and wellness markets.